Article
Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a FLT3 mutation.
Future oncology (London, England) - 1 Jan 2021
Ballesta-López Octavio, Solana-Altabella Antonio, Megías-Vericat Juan Eduardo, Martínez-Cuadrón David, Montesinos Pau
Abstract excerpt
The prognosis of patients with relapsed or refractory acute myeloid leukemia (R/R AML) is dismal with salvage standard approaches, and mutations of FMS-like tyrosine kinase 3 (FLT3) gene, occurring in around 30% of AML patients may confer even poorer outcomes. Several targeted tyrosine kinase inh...
Topics
- Aniline Compounds
- Drug Resistance, Neoplasm
- Humans
- Leukemia, Myeloid, Acute
- Molecular Targeted Therapy
- Mutation
- Prognosis
- Protein Kinase Inhibitors
- Pyrazines
- Recurrence
- Retreatment
- Treatment Outcome
- fms-Like Tyrosine Kinase 3